5323.0000 -32.50 (-0.61%)
NSE Mar 16, 2026 15:52 PM
Volume: 204.3K
 

5323.00
-0.61%
Motilal Oswal
With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.
Number of FII/FPI investors increased from 589 to 613 in Dec 2025 qtr.
More from Alkem Laboratories Ltd.
Recommended